scispace - formally typeset
M

Masashi Mizokami

Researcher at Nagoya City University

Publications -  684
Citations -  37168

Masashi Mizokami is an academic researcher from Nagoya City University. The author has contributed to research in topics: Hepatitis B virus & Hepatitis C virus. The author has an hindex of 85, co-authored 650 publications receiving 34868 citations. Previous affiliations of Masashi Mizokami include National Institute of Advanced Industrial Science and Technology & University of Florida.

Papers
More filters
Journal ArticleDOI

Virological and Clinical Characteristics of Hepatitis B Virus Genotype A

TL;DR: The virological and clinical characteristics of HBV genotype A will be useful in elucidating the association among persistent viral infection, host genetic factors, and treatment in future studies.
Journal ArticleDOI

Frequency and Characteristics of Occult Hepatitis B Infection Among Hepatocellular Carcinoma Patients in Japan.

TL;DR: There was no correlation between OBI and anti-HBV antibodies, but fewer patients with OBI had high inflammatory activity, suggesting that factors other than inflammation may be involved in HCC carcinogenesis in patients withOBI.
Journal ArticleDOI

Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan.

TL;DR: Whether particular hepatitis C virus subtypes are spreading among injecting drug users in Yamaguchi prefecture, on the south‐western tip of the island of Honshu in Japan, as found in European countries is examined.
Journal ArticleDOI

Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C.

TL;DR: It is concluded that hepatic expression of HCV core and NS4 antigens parallels serum HCV-RNA levels and IFN therapy reduces hepaticexpression of these viral antigen.
Journal ArticleDOI

Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9

TL;DR: The possible use of nickase-Cas9 and d- Cas9 with a pair of sgRNAs for eliminating HBV DNA from the livers of chronic hepatitis B patients with low risk of undesirable off-target mutation on the host genome is suggested.